Kairos Pharma Ltd. (KAPA)
1.73
-0.08
(-4.42%)
USD |
NYAM |
Sep 18, 16:00
1.75
+0.02
(+1.16%)
After-Hours: 20:00
Kairos Pharma Net Income (Quarterly) : -1.388M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.388M |
| March 31, 2026 | -1.654M |
| December 31, 2025 | -1.365M |
| September 30, 2025 | -1.398M |
| June 30, 2025 | -1.422M |
| March 31, 2025 | -1.262M |
| December 31, 2024 | -0.98M |
| September 30, 2024 | -1.047M |
| June 30, 2024 | -0.253M |
| Date | Value |
|---|---|
| March 31, 2024 | -0.323M |
| December 31, 2023 | -1.118M |
| September 30, 2023 | -0.312M |
| June 30, 2023 | -0.236M |
| March 31, 2023 | -0.146M |
| December 31, 2022 | -0.196M |
| September 30, 2022 | -0.234M |
| June 30, 2022 | -0.385M |
| March 31, 2022 | -0.235M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.388M |
| EPS Diluted (Quarterly) | -0.4536 |
| Enterprise Value | 2.669M |
| Earnings Yield | -112.6% |
| Normalized Earnings Yield | -108.72 |